Close Menu

Akonni

The Frederick, Maryland-based firm has received regulatory clearance for a multiplexed array-based assay after more than 15 years in development.

Akonni has received clearance for a molecular diagnostic instrument and a saliva-based pharmacogenomics test for warfarin metabolism.

The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.

Upon clearance of the platform, the company will commercialize the TruDiagnosis, an IVD system for genotyping multiple genes in a DNA sample, this year.

The firm plans to make the molecular testing system accessible to low-income countries, in part by reducing costs using reel-to-reel manufacturing.

The exclusive two-way licensing deal also allows Akonni to commercialize Righton's molecular diagnostic tests outside of China.

The grant was awarded under a program designed to help small businesses transition NIH-funded projects into the commercialization stage.

The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.

The funding will be used in part to prepare an FDA submission for a clinical IVD pharmacogenomic test for its TruDx 2000 microarray platform.

An RT-qPCR-based assay of antigen-stimulated blood is a possible next-gen approach for latent TB detection, a Cepheid executive noted in an accompanying commentary.

Pages

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.